Antiplatelet therapy: Aspirin resistance and all that jazz!

Clinical and Applied Thrombosis/Hemostasis

Volumn 19, Issue 1, 2013, Pages 5-18

  Divani, Afshin A ^a   Zantek, Nicole D ^b   Borhani Haghighi, Afshin ^c   Rao, Gundu H R ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

acetylsalicylic acid; antiplatelet therapy; arachidonic acid; aspirin resistance; cyclooxygenase; prostacycline; stroke; thromboxane; vascular disease

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ATENOLOL; ATORVASTATIN; CILOSTAZOL; CLOPIDOGREL; DALTEPARIN; DIPYRIDAMOLE; LOW MOLECULAR WEIGHT HEPARIN; SARPOGRELATE; SIMVASTATIN; SULFINPYRAZONE; TICLOPIDINE; TRIFLUSAL; WARFARIN;

CAROTID ARTERY STENTING; CEREBROVASCULAR ACCIDENT; HUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; THROMBOELASTOGRAPHY; TRANSIENT ISCHEMIC ATTACK;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; ATHEROSCLEROSIS; BLOOD PLATELETS; DRUG RESISTANCE; HUMANS; STROKE; THROMBOSIS;

EID: 84871551350     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029612449197     Document Type: Review

References (107)

1. Miner J, Hoffhines A. The discovery of aspirin's antithrombotic effects. Tex Heart Inst J. 2007 ; 34 (2). 179-186
2. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack. Stroke. 2011 ; 42 (1). 227-276
3. Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011 ; 42 (2). 517-584
4. Brott TG, Halperin JL, Abbara S, et al. ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/ CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: a report of the american college of cardiology foundation/American Heart Association task force on practice guidelines, and the American Stroke Association, american association of neuroscience nurses, american association of neurological surgeons, american college of radiology, american society of neuroradiology, congress of neurological surgeons, society of atherosclerosis imaging and prevention, society for cardiovascular angiography and interventions, society of interventional radiology, society of neurointerventional surgery, society for vascular medicine, and society for vascular surgery. Stroke. 2011 2011 ; 42 (8). e464 - e540
5. Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology. 2008 ; 135 (1). 41-60
6. Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol. 2005 ; 95 (10). 1218-1222
7. Farrell B, Godwin J, Richards S, Warlow C. The united kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991 ; 54 (12). 1044-1054
8. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 ; 324 (7329). 71-86
9. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol. 2004 ; 24 (11). 1980-1987
10. Kuliczkowski W, Witkowski A, Polonski L, et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the working group on antiplatelet drugs resistance appointed by the section of cardiovascular interventions of the polish cardiac society, endorsed by the working group on thrombosis of the european society of cardiology. Eur Heart J. 2009 ; 30 (4). 426-435
11. Eikelboom JW, Hankey GJ. Aspirin resistance: a new independent predictor of vascular events?. J Am Coll Cardiol. 2003 ; 41 (6). 966-968
12. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002 ; 105 (14). 1650-1655
13. Grotemeyer KH. Effects of acetylsalicylic acid in stroke patients evidence of nonresponders in a subpopulation of treated patients. Thromb Res. 1991 ; 63 (6). 587-593
14. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res. 1993 ; 71 (5). 397-403
15. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001 ; 88 (3). 230-235
16. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003 ; 41 (6). 961-965
17. Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke. 1994 ; 25 (12). 2331-2336
18. Howard PA. Aspirin resistance. Ann Pharmacother. 2002 ; 36 (10). 1620-1624
19. Hurlen M, Seljeflot I, Arnesen H. The effect of different antithrombotic regimens on platelet aggregation after myocardial infarction. Scand Cardiovasc J. 1998 ; 32 (4). 233-237
20. Mueller MR, Salat A, Stangl P, et al. Variable platelet response to low-dose asa and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost. 1997 ; 78 (3). 1003-1007
21. Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 2003 ; 89 (5). 783-787
22. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 ; 126 (suppl 3). 234S - 264
23. Pollack A. For some, aspirin may not help hearts. The New York Times. 2004 ;:
24. Sane DC, McKee SA, Malinin AI, Serebruany VL. Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. Am J Cardiol. 2002 ; 90 (8). 893-895
25. Smout J, Stansby G. Aspirin resistance. Br J Surg. 2002 ; 89 (1). 4-5
26. Weber AA, Przytulski B, Schanz A, Hohlfeld T, Schror K. Towards a definition of aspirin resistance: a typological approach. Platelets. 2002 ; 13 (1). 37-40
27. Wu KK, Hoak JC. A new method for the quantitative detection of platelet aggregates in patients with arterial insufficiency. Lancet. 1974 ; 2 (7886). 924-926
28. Yilmaz MB, Balbay Y, Korkmaz S. Aspirin resistance. Anadolu Kardiyol Derg. 2004 ; 4 (1). 59-62
29. Zimmermann N, Wenk A, Kim U, et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation. 2003 ; 108 (5). 542-547
30. Hovens MM, Snoep JD, Eikenboom JC, van der Bom JG, Mertens BJ, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J. 2007 ; 153 (2). 175-181
31. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost. 2003 ; 1 (8). 1710-1713
32. Eikelboom JW, Hankey GJ, Thom J, et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation. 2008 ; 118 (17). 1705-1712
33. Berrouschot J, Schwetlick B, von Twickel G, et al. Aspirin resistance in secondary stroke prevention. Acta Neurol Scand. 2006 ; 113 (1). 31-35
34. Englyst NA, Horsfield G, Kwan J, Byrne CD. Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity. J Cereb Blood Flow Metab. 2008 ; 28 (6). 1196-1203
35. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008 ; 336 (7637). 195-198
36. Georgiadis AL, Cordina SM, Vazquez G, et al. Aspirin treatment failure and the risk of recurrent stroke and death among patients with ischemic stroke. J Stroke Cerebrovasc Dis. 2011 ;:
37. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet. 2006 ; 367 (9510). 606-617
38. Violi F, Pignatelli P. The need for a consistent definition of "aspirin resistance". J Thromb Haemost. 2006 ; 4 (7). 1618-1619
39. Rao GH, White JG. Epinephrine potentiation of arachidonate-induced aggregation of cyclooxygenase-deficient platelets. Am J Hematol. 1981 ; 11 (4). 355-366
40. Favaloro EJ. Clinical utility of the pfa-100. Semin Thromb Hemost. 2008 ; 34 (8). 709-733
41. Favaloro EJ. The utility of the pfa-100 in the identification of von willebrand disease: a concise review. Semin Thromb Hemost. 2006 ; 32 (5). 537-545
42. Eugster M, Reinhart WH. The influence of the haematocrit on primary haemostasis in vitro. Thromb Haemost. 2005 ; 94 (6). 1213-1218
43. Harrison P, Robinson MS, Mackie IJ, et al. Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis. Blood Coagul Fibrinolysis. 1999 ; 10 (1). 25-31
44. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol. 2003 ; 250 (1). 63-66
45. Bugnicourt JM, Roussel B, Garcia PY, Canaple S, Lamy C, Godefroy O. Aspirin non-responder status and early neurological deterioration: a prospective study. Clin Neurol Neurosurg. 2011 ; 113 (3). 196-201
46. Chen WH, Cheng X, Lee PY, et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med. 2007 ; 120 (7). 631-635
47. Poston RS, Gu J, Brown JM, et al. Endothelial injury and acquired aspirin resistance as promoters of regional thrombin formation and early vein graft failure after coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2006 ; 131 (1). 122-130
48. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol. 2005 ; 46 (9). 1705-1709
49. Frelinger AL, Li Y, Linden MD, et al. Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost. 2008 ; 6 (12). 2035-2044
50. Grove EL, Hvas AM, Johnsen HL, et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost. 2010 ; 103 (6). 1245-1253
51. Wurtz M, Grove EL, Wulff LN, et al. Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. JACC Cardiovasc Interv. 2010 ; 3 (8). 828-835
52. Frelinger AL, Li Y, Linden MD, et al. Association of cyclooxygenase-1- dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation. 2009 ; 120 (25). 2586-2596
53. Catella F, Healy D, Lawson JA. FitzGerald GA. 11-dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci U S A. 1986 ; 83 (16). 5861-5865
54. Patrono C, Ciabattoni G, Pugliese F, Pierucci A, Blair IA, FitzGerald GA. Estimated rate of thromboxane secretion into the circulation of normal humans. J Clin Invest. 1986 ; 77 (2). 590-594
55. Bruno A, McConnell JP, Cohen SN, et al. Serial urinary 11-dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction. Stroke. 2004 ; 35 (3). 727-730
56. Bruno A, McConnell JP, Mansbach I, et al. Aspirin and urinary 11-dehydrothromboxane b2 in african american stroke patients. Stroke. 2002 ; 33 (1). 57-60
57. Hishinuma T, Yu GSP, Takabatake M, et al. Analysis of the thromboxane/prostacyclin balance in human urine by gas chromatography/selected ion monitoring: abnormalities in diabetics. Prostaglandins Leukot Essent Fatty Acids. 1996 ; 54 (6). 445-449
58. McConnell JP, Cheryk LA, Durocher A, et al. Urinary 11-dehydro- thromboxane B2 and coagulation activation markers measured within 24 h of human acute ischemic stroke. Neurosci Lett. 2001 ; 313 (1-2). 88-92
59. Mizugakia M, Hishinuma T, Matsumura E, et al. Monitoring of the thromboxane a2/prostacyclin ratio in the urine of patients with retinal vascular occlusion through the low-dose-aspirin therapy using the gas chromatography/selected ion monitoring method. Prostaglandins Other Lipid Mediat. 1999 ; 58 (5-6). 253-262
60. Montine TJ, Sonnen JA, Milne G, Baker LD, Breitner JC. Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in adapt. PLoS One. 2010 ; 5 (2). e9340
61. Smith CJ, Fischer TH, Heavner DL, et al. Urinary thromboxane, prostacyclin, cortisol, and 8-hydroxy-2′-deoxyguanosine in nonsmokers exposed and not exposed to environmental tobacco smoke. Toxicol Sci. 2001 ; 59 (2). 316-323
62. Weber AA, Liesener S, Schanz A, Hohlfeld T, Schror K. Habitual smoking causes an abnormality in platelet thromboxane a2 metabolism and results in an altered susceptibility to aspirin effects. Platelets. 2000 ; 11 (3). 177-182
63. Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-induced Platelet Effect (ASPECT) Study. Circulation. 2007 ; 115 (25). 3156-3164
64. Brambilla M, Parolari A, Camera M, et al. Effect of two doses of aspirin on thromboxane biosynthesis and platelet function in patients undergoing coronary surgery. Thromb Haemost. 2010 ; 103 (3). 516-524
65. Henry P, Vermillet A, Boval B, et al. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost. 2011 ; 105 (2). 336-344
66. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J. 2007 ; 28 (14). 1702-1708
67. Rao GH. Aspirin resistance: a fact or a myth?. Exp Clin Cardiol. 2005 ; 10 (1). 17-20
68. Rao GHR, Divani AA. Past present and future of anti-platelet therapy. J Vascular and Interventional Neurology. 2008 ; 1: 57-60
69. Rao GH, Michiels JJ. Aspirin resistance: does it exist?. Semin Thromb Hemost. 2007 ; 33 (2). 210-214
70. Rao GH. Aspirin: expectations and limitations. J Assoc Physicians India. 2008 ; 56: 317-319
71. Altman R, Luciardi H, Muntaner J, Herrera R. The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?. Thromb J. 2004 ; 2 (1). 1
72. Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res. 2002 ; 108 (1). 37-42
73. Coleman JL, Wang JC, Simon DI. Determination of individual response to aspirin therapy using the accumetrics ultegra rpfa-asa system. Point of Care. 2004 ; 3 (2). 77-82
74. De Caetano C, Cerletti C. Aspirin resistance: a revival of platelet aggregation tests?. J Thromb Haemost. 2003 ; 1 (9). 2048-2050
75. Feuring M, Haseroth K, Janson CP, Falkenstein E, Schmidt BM, Wehling M. Inhibition of platelet aggregation after intake of acetylsalicylic acid detected by a platelet function analyzer (PFA-100). Int J Clin Pharmacol Ther. 1999 ; 37 (12). 584-588
76. Malinin A, Spergling M, Muhlestein B, Steinhubl S, Serebruany V. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul Fibrinolysis. 2004 ; 15 (4). 295-301
77. McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost. 2002 ; 88 (5). 711-715
78. Sambola A, Heras M, Escolar G, et al. The PFA-100 detects sub-optimal antiplatelet responses in patients on aspirin. Platelets. 2004 ; 15 (7). 439-446
79. Singh S, Kothari SS, Bahl VK. Aspirin resistance: myth or reality?. Indian Heart J. 2003 ; 55 (3). 217-222
80. Divani AA, Majidi S, Barrett AM, Noorbaloochi S, Luft AR. Consequences of stroke in community-dwelling elderly: the health and retirement study, 1998 to 2008. Stroke. 2011 ; 42 (7). 1821-1825
81. Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med. 1990 ; 150 (4). 841-845
82. Wang PS, Bohn RL, Knight E, Glynn RJ, Mogun H, Avorn J. Noncompliance with antihypertensive medications. J Gen Intern Med. 2002 ; 17 (7). 504-511
83. Carney RM, Freedland KE, Eisen SA, Rich MW, Jaffe AS. Major depression and medication adherence in elderly patients with coronary artery disease. Health Psychol. 1995 ; 14 (1). 88-90
84. Rieckmann N, Kronish IM, Haas D, et al. Persistent depressive symptoms lower aspirin adherence after acute coronary syndromes. Am Heart J. 2006 ; 152 (5). 922-927
85. Sappok T, Faulstich A, Stuckert E, Kruck H, Marx P, Koennecke HC. Compliance with secondary prevention of ischemic stroke: a prospective evaluation. Stroke. 2001 ; 32 (8). 1884-1889
86. Komiya T, Kudo M, Urabe T, Mizuno Y. Compliance with antiplatelet therapy in patients with ischemic cerebrovascular disease. Assessment by platelet aggregation testing. Stroke. 1994 ; 25 (12). 2337-2342
87. Cuisset T, Frere C, Quilici J, et al. Aspirin noncompliance is the major cause of "aspirin resistance" in patients undergoing coronary stenting. Am Heart J. 2009 ; 157 (5). 889-893
88. Schwartz KA, Schwartz DE, Barber K, Reeves M, De Franco AC. Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. J Transl Med. 2008 ; 6: 46
89. Cotter G, Shemesh E, Zehavi M, et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin?. Am Heart J. 2004 ; 147 (2). 293-300
90. Watala C, Boncler M, Gresner P. Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus. Pharmacol Rep. 2005 ; 57 (suppl). 42-58
91. Zimmermann N, Weber AA, Hohlfeld T. Aspirin "resistance". Herz. 2008 ; 33 (4). 270-278
92. Zuern CS, Lindemann S, Gawaz M. Platelet function and response to aspirin: gender-specific features and implications for female thrombotic risk and management. Semin Thromb Hemost. 2009 ; 35 (3). 295-306
93. Dawson J, Quinn T, Rafferty M, et al. Aspirin resistance and compliance with therapy. Cardiovasc Ther. 2011 ; 29 (5). 301-307
94. Beigel R, Hod H, Fefer P, et al. Relation of aspirin failure to clinical outcome and to platelet response to aspirin in patients with acute myocardial infarction. Am J Cardiol. 2011 ; 107 (3). 339-342
95. Beigel R, Matetzky S, Fefer P, Dvir D, Hod H. Aspirin-issues in daily practice: an update. Isr Med Assoc J. 2007 ; 9 (4). 221-226
96. Pulcinelli FM, Riondino S, Celestini A, et al. Persistent production of platelet thromboxane a2 in patients chronically treated with aspirin. J Thromb Haemost. 2005 ; 3 (12). 2784-2789
97. Rao GHR, Escolar G, White JG. Epinephrine reverses the inhibitory influence of aspirin on platelet-vessel wall interactions. Thromb Res. 1986 ; 44 (1). 65-74
98. Shantsila E. Lip G. "Aspirin resistance" or treatment non-compliance: which is to blame for cardiovascular complications?. J Transl Med. 2008 ; 6: 47
99. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004 ; 364 (9431). 331-337
100. Markus HS, Droste DW, Kaps M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the clopidogrel and aspirin for reduction of emboli in symptomatic carotid stenosis (CARESS) trial. Circulation. 2005 ; 111 (17). 2233-2240
101. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation. N Engl J Med. 2001 ; 345 (7). 494-502
102. Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation. 2004 ; 110 (10). 1202-1208
103. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 ; 357 (20). 2001-2015
104. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 ; 361 (11). 1045-1057
105. Pettersen AA, Seljeflot I, Abdelnoor M, Arnesen H. Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. Scand Cardiovasc J. 2004 ; 38 (6). 353-356
106. Cheng X, Chen W-H, Simon DI. Aspirin resistance or variable response or both?. Am J Cardiol. 2006 ; 98 (10). S11 - S17
107. Geske FJ, Guyer KE, Ens G. Aspirinworks: a new immunologic diagnostic test for monitoring aspirin effect. Mol Diagn Ther. 2008 ; 12 (1). 51-54